certify

Marina Turea Marina is passionate about all emerging technologies in the healthcare space and love to write about all of them.

March 26, 2023 340 Views
Merck & Co. Inc.’s experimental TIGIT drug, vibostolimab, failed to meet its primary endpoint in a Phase 2 ...
banner
Adsense